Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.
- befree-2016 importedOn "2016-02-19" NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.
- NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_assertion wasGeneratedBy ECO_0000203 NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.
- NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_assertion wasDerivedFrom befree-2016 NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.
- NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_assertion SIO_000772 21431419 NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.
- NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_assertion evidence source_evidence_literature NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.
- NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_assertion description "[The FDA approval of bevacizumab (Avastin®, Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881864.RA9jnJsXRerMZJzQg82Tg-FRSw_mACNVQfy9_2yhVkUtg130_provenance.